Company Overview of LAM Therapeutics, Inc.
LAM Therapeutics, Inc. develops precision therapeutics and companion diagnostics for cancer and rare diseases. The company offers LAM-001, an inhaled mTOR kinase inhibitor for lymphangioleiomyomatosis; and LAM-002, a PIKfyve kinase inhibitor for B-cell non-Hodgkin lymphoma. It also provides LAM-003, an orally active, small-molecule, and immune-modulating anti-cancer drug; and other clinical stage drugs. The company was founded in 2013 and is based in Guilford, Connecticut.
530 Old Whitfield Street
Guilford, CT 06437
Founded in 2013
Key Executives for LAM Therapeutics, Inc.
Similar Private Companies By Industry
|Praetego, Inc.||United States|
|1st Order Pharmaceuticals, Inc.||United States|
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|Tax Management Inc||United States|
|John F. Kennedy Center For The Performing Arts||United States|
|NYC2012, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact LAM Therapeutics, Inc., please visit www.lamtherapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.